Medicinal cannabis and veterans: DVA tightens prescribing rules

A reset for veteran cannabis prescribing

Medicinal cannabis has shifted from fringe debate to everyday clinical conversation. For some veterans living with chronic pain, PTSD and other service-related conditions, it has offered an alternative when conventional therapies have failed.

Access through the Department of Veterans’ Affairs is now more tightly framed.

In updated guidance released this month, DVA confirmed it is strengthening its medicinal cannabis approval processes to ensure prescribing is clinically justified, coordinated and safe. For veterans seeking DVA-funded products, the pathway remains open, but the bar is clearer and higher.

In practical terms, applications initiated through telehealth-only or high-volume cannabis clinics, particularly those without an established therapeutic relationship, are unlikely to be approved. DVA has signalled concern about fragmented care models and prescribing that occurs outside a veteran’s broader clinical context.

For healthcare leaders, this is more than an administrative adjustment. It is a clear statement about how emerging therapies should be governed in publicly funded systems: with documentation, discipline and continuity.

What has changed?

Medicinal cannabis has never been automatically funded under DVA arrangements. Individual approval is required, generally where conventional treatments have been trialled and found ineffective or not tolerated.

The updated framework reinforces several core principles:

• A genuine therapeutic relationship: The prescribing clinician must be involved in the veteran’s ongoing care, not acting as a one-off cannabis provider.
• Comprehensive clinical assessment: This includes review of mental health history, substance use risk, comorbidities and current medications.
• Evidence-based justification: Applications must clearly articulate clinical indication, previous treatment pathways and rationale for cannabis use.
• Ongoing monitoring and coordination: Follow-up, dose review and communication with the veteran’s usual GP or specialist are expected.

DVA’s position is not a prohibition. Veterans can still access funded medicinal cannabis where clinically appropriate. But prescribers must demonstrate that decisions sit within an integrated, accountable care model.

A warning shot for volume-based models

Australia has seen rapid growth in private cannabis clinics, many operating primarily online. While these services may comply with Therapeutic Goods Administration pathways, DVA’s stance highlights an important distinction between regulatory permission and funding approval.

Public funding attracts higher scrutiny.

Clinics prescribing to veterans should review:

• Documentation standards and assessment protocols
• Evidence of continuity of care
• Communication pathways with the patient’s usual GP or specialist
• Risk management processes around mental health and substance misuse

For practice owners, this is also a governance issue. The reputational risk of being perceived as a transactional “script factory” is significant, particularly when treating vulnerable cohorts such as veterans.

The broader policy signal

DVA’s move sits within a wider tightening of digital health and prescribing oversight across Australia. Governments are increasingly focused on accountability, interoperability and demonstrable clinical value.

Veterans represent a complex patient population, often living with layered trauma, chronic pain and co-existing mental health conditions. The department’s updated position reflects a preference for integrated, relationship-based care over isolated prescribing encounters.

For innovators in the medicinal cannabis and digital health sectors, the message is not anti-innovation. It is pro-governance.

Clinics that invest in structured assessment frameworks, collaborative care pathways and measurable outcomes will be better positioned to work with government funders over the long term.

What healthcare leaders should do now

If your clinic prescribes medicinal cannabis to veterans, this is the moment for internal review. You should be asking:

• Are we embedded in the patient’s broader care journey?
• Are our assessments comprehensive and defensible under audit?
• Do we have documented follow-up and monitoring pathways?
• Can we clearly justify clinical decisions in writing?

Policy shifts rarely happen in isolation. This one reinforces a broader principle shaping Australian healthcare: innovation must move in step with accountability.

The opportunity for healthcare leaders is clear. Build prescribing models that are not only legal, but durable, evidence-led and trusted.

Because in publicly funded care, trust is the ultimate currency.